The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

iwMyeloma 2016 | Tolerability of monoclonal antibodies in multiple myeloma

Name: Tolerability of monoclonal antibodies in multiple myeloma
Uploaded: 2016-04-22T00:00:00.000Z
Duration: 1 min 13 s
Description: Thomas Martin, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the tolerability of monoclonal antibodies. According to Prof Martin, monoclonal antibodies are well tolerated, however, at the first infusion there can be infusion-related reactions. Recorded at the Myeloma 2016 meeting held in Boston, MA.

Thomas Martin • 22 Apr 2016

iwMyeloma 2016

Multiple Myeloma Antibodies

Thomas Martin, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the tolerability of monoclonal antibodies. According to Prof Martin, monoclonal antibodies are well tolerated, however, at the first infusion there can be infusion-related reactions.
Recorded at the Myeloma 2016 meeting held in Boston, MA.